再生医学：转变药物发现与开发模式。
Regenerative medicine: transforming the drug discovery and development paradigm.
作者信息
Karathanasis Sotirios K
机构信息
Cardiovascular & Metabolic Diseases, Gaithersburg, Maryland 20878.
出版信息
Cold Spring Harb Perspect Med. 2014 Aug 1;4(8):a014084. doi: 10.1101/cshperspect.a014084.
Despite the explosion of knowledge in basic biological processes controlling tissue regeneration and the growing interest in repairing/replacing diseased tissues and organs through various approaches (e.g., small and large molecule therapeutics, stem cell injection, tissue engineering), the pharmaceutical industry (pharma) has been reluctant to fully adopt these technologies into the traditional drug discovery and research and development (R&D) process. In this article, I discuss knowledge-base gaps and other possible factors that may delay full incorporation of these innovations in pharma R&D. I hope that this discussion will illuminate key issues that currently limit synergistic relationships between pharma and academic institutions and may even stimulate initiation of such collaborative research.
尽管在控制组织再生的基本生物学过程方面知识激增，并且人们对通过各种方法（例如小分子和大分子疗法、干细胞注射、组织工程）修复/替换患病组织和器官的兴趣日益浓厚，但制药行业一直不愿将这些技术完全纳入传统的药物发现及研发过程。在本文中，我将探讨知识库差距以及其他可能会延迟这些创新在制药研发中全面应用的因素。我希望这一讨论能够阐明当前限制制药公司与学术机构之间协同关系的关键问题，甚至可能促使此类合作研究的开展。
Zotero 插件